Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Randomised Phase II Study to Assess the Safety and Resectability in Patients With Initially Unresectable Liver Metastases Secondary to Colorectal Cancer Receiving First-line Treatment Either With mFOLFOX-6 Plus Bevacizumab or FOLFOXIRI Plus Bevacizumab (OLIVIA)

NCT00778102 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00778102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00778102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Randomised Phase II Study to Assess the Safety and Resectability in Patients With Initially Unresectable Liver Metastases Secondary to Colorectal Cancer Receiving First-line Treatment Either With mFOLFOX-6 Plus Bevacizumab or FOLFOXIRI Plus Bevacizumab (OLIVIA)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2008
Completion date
October 31, 2013
Enrollment
80 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer